{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:57Z","timestamp":1778056557308,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Major atrial fibrillation (AF) guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over warfarin, except in rare clinical circumstances based on 4 randomized controlled trials comparing each NOAC with warfarin. We aimed to investigate the current NOAC prescription behaviors in alignment with the recent clinical evidence available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We conducted a cross-sectional analysis of NOAC-using patients with non-valvular atrial fibrillation (NVAF) who were aged \u226565 years on the index date (July 1, 2018) based on nationwide claims data. The types of NOACs being taken were analyzed using chi-squared tests, and factors influencing NOAC selection were identified using multinomial logistic regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 6,061 patients were included. Among the 4 NOACs, rivaroxaban was the most used NOAC. Patients aged \u226575 years (odds ratio [OR] = 1.270, confidence interval [CI] = 1.089-1.450) and women (OR = 1.148, CI = 1.011-1.284) were more likely to use apixaban relative to rivaroxaban. Patients with prior stroke\/transient ischemic attack\/thromboembolism had higher odds of using dabigatran (OR = 1.508, CI = 1.312-1.704) and apixaban (OR = 1.186, CI = 1.026-1.346). Patients with renal disease had higher odds of using apixaban (OR = 1.466, 95% CI = 1.238-1.693). These findings are consistent with the efficacy and safety profiles reported in pivotal trials and observational studies comparing individual NOACs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Among the 4 NOACs, rivaroxaban was the most commonly used NOAC. Apixaban was preferred for patients aged \u226575 years, females, and patients with renal disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10742484211049919","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T08:26:26Z","timestamp":1632471986000},"page":"656-664","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation"],"prefix":"10.1177","volume":"26","author":[{"given":"Susin","family":"Park","sequence":"first","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-5131","authenticated-orcid":false,"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Pusan National University, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"bibr1-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.11.1354"},{"key":"bibr2-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2622"},{"key":"bibr3-10742484211049919","author":"AGENCY EM","year":"2010","journal-title":"European Medicines Agency"},{"key":"bibr4-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"bibr5-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1586\/erc.11.21"},{"key":"bibr6-10742484211049919","unstructured":"Administration FaD. Drug Approval Package: Xarelto (rivaroxaban). 2011.\n                      wwwaccessdatafdagov"},{"key":"bibr7-10742484211049919","unstructured":"Administration FaD. Drug Approval Package: Eliquis (apixaban). 2012.\n                      wwwaccessdatafdagov"},{"key":"bibr8-10742484211049919","unstructured":"Administration FaD. Drug Approval Package: Savaysa (edoxaban). 2015.\n                      wwwaccessdatafdagov"},{"key":"bibr9-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"bibr10-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.10.973"},{"key":"bibr11-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01236-6"},{"key":"bibr12-10742484211049919","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"bibr13-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-0670"},{"key":"bibr14-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.004424"},{"key":"bibr15-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.06.177"},{"key":"bibr16-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189495"},{"key":"bibr17-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.011"},{"key":"bibr18-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.040"},{"key":"bibr19-10742484211049919","doi-asserted-by":"publisher","DOI":"10.3904\/kjm.2018.93.2.87.e1"},{"key":"bibr20-10742484211049919","doi-asserted-by":"publisher","DOI":"10.5694\/mja18.00646"},{"key":"bibr21-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.11.033"},{"key":"bibr22-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13299"},{"key":"bibr23-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1038\/srep31477"},{"key":"bibr24-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2158"},{"key":"bibr25-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(20)31145-1"},{"key":"bibr26-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"bibr27-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"bibr28-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"bibr29-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"bibr30-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000665"},{"key":"bibr31-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"bibr32-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.072"},{"key":"bibr33-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.119.025536"},{"key":"bibr34-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz086"},{"key":"bibr35-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12628"},{"key":"bibr36-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017012377"},{"key":"bibr37-10742484211049919","doi-asserted-by":"publisher","DOI":"10.5603\/KP.a2018.0027"},{"key":"bibr38-10742484211049919","doi-asserted-by":"publisher","DOI":"10.4082\/kjfm.20.0062"},{"key":"bibr39-10742484211049919","unstructured":"Service NHI. National health insurance system of Korea. 2015. Accessed July 9, 2021. www.kobia.kr\/skin\/bbs\/downloads_e2\/download.php?tbl=policy_report&no=401"},{"key":"bibr40-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5058-1"},{"key":"bibr41-10742484211049919","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e163"},{"key":"bibr42-10742484211049919","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2019.0207"},{"issue":"12","key":"bibr43-10742484211049919","first-page":"860","volume":"38","author":"Diener HC","year":"2017","journal-title":"Eur Heart J"},{"key":"bibr44-10742484211049919","doi-asserted-by":"publisher","DOI":"10.3904\/kjm.2018.93.2.110"},{"key":"bibr45-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1177\/2040622317720106"},{"key":"bibr46-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu046"},{"key":"bibr47-10742484211049919","doi-asserted-by":"publisher","DOI":"10.3904\/kjm.2019.94.1.17"},{"key":"bibr48-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.11.084"},{"key":"bibr49-10742484211049919","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.028825"},{"issue":"5","key":"bibr50-10742484211049919","first-page":"975","volume":"116","author":"Lip GY","year":"2016","journal-title":"Thromb Haemostasis"},{"key":"bibr51-10742484211049919","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484211049919","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10742484211049919","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10742484211049919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:43:30Z","timestamp":1777394610000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10742484211049919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1177\/10742484211049919"],"URL":"https:\/\/doi.org\/10.1177\/10742484211049919","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}